{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:51:46Z","timestamp":1775026306194,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,24]]},"DOI":"10.7759\/cureus.8814","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T01:33:05Z","timestamp":1593048785000},"source":"Crossref","is-referenced-by-count":3,"title":["Acute Kidney Injury Caused by Levetiracetam in a Patient With Status Epilepticus"],"prefix":"10.7759","author":[{"given":"Burak","family":"Erdinc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snigdha","family":"Ghanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Andreev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim O","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonu","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos PN","year":"2000","unstructured":"Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000, 85:77-85. 10.1016\/s0163-7258(99)00052-2","journal-title":"Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2003.25.2.723686","article-title":"The pharmacokinetic characteristics of levetiracetam","volume":"25","author":"Patsalos PN","year":"2003","unstructured":"Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol. 2003, 25:123-129. 10.1358\/mf.2003.25.2.723686","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0237-7","article-title":"Levetiracetam pharmacokinetics in Japanese subjects with renal impairment","volume":"34","author":"Yamamoto J","year":"2014","unstructured":"Yamamoto J, Toublanc N, Kumagai Y, Stockis A. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. Clin Drug Investig. 2014, 34:819-828. 10.1007\/s40261-014-0237-7","journal-title":"Clin Drug Investig"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0920-1211(03)00080-9","article-title":"The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study","volume":"54","author":"Morrell MJ","year":"2003","unstructured":"Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003, 54:153-161. 10.1016\/s0920-1211(03)00080-9","journal-title":"Epilepsy Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.06.002","article-title":"Levetiracetam as a possible contributor to acute kidney injury","volume":"36","author":"Spengler DC","year":"2014","unstructured":"Spengler DC, Montouris GD, Hohler AD. Levetiracetam as a possible contributor to acute kidney injury. Clin Ther. 2014, 36:1303-1306. 10.1016\/j.clinthera.2014.06.002","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.08.007","article-title":"Levetiracetam-induced interstitial nephritis in a patient with glioma","volume":"19","author":"Mahta A","year":"2012","unstructured":"Mahta A, Kim RY, Kesari S. Levetiracetam-induced interstitial nephritis in a patient with glioma. J Clin Neurosci. 2012, 19:177-178. 10.1016\/j.jocn.2011.08.007","journal-title":"J Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2009.01.011","article-title":"Levetiracetam induced interstitial nephritis and renal failure","volume":"41","author":"Hurwitz KA","year":"2009","unstructured":"Hurwitz KA, Ingulli EG, Krous HF. Levetiracetam induced interstitial nephritis and renal failure. Pediatr Neurol. 2009, 41:57-58. 10.1016\/j.pediatrneurol.2009.01.011","journal-title":"Pediatr Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7873813","article-title":"Rhabdomyolysis in a hospitalized 16-year-old boy: a rarely reported underlying cause","volume":"2016","author":"Singh R","year":"2016","unstructured":"Singh R, Patel DR, Pejka S. Rhabdomyolysis in a hospitalized 16-year-old boy: a rarely reported underlying cause. Case Rep Pediatr. 2016, 2016:7873813. 10.1155\/2016\/7873813","journal-title":"Case Rep Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07490618","article-title":"Population-based study of risk of AKI with levetiracetam","volume":"14","author":"Yau K","year":"2019","unstructured":"Yau K, Burneo JG, Jandoc R, et al.. Population-based study of risk of AKI with levetiracetam. Clin J Am Soc Nephrol. 2019, 14:17-26. 10.2215\/CJN.07490618","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s1059-1311(02)00292-3","article-title":"An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy","volume":"12","author":"Abou-Khalil B","year":"2003","unstructured":"Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Seizure. 2003, 12:141-149. 10.1016\/s1059-1311(02)00292-3","journal-title":"Seizure"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.09.005","article-title":"Efficacy and safety of levetiracetam 1000-3000 mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study","volume":"63","author":"Beran RG","year":"2005","unstructured":"Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ. Efficacy and safety of levetiracetam 1000-3000 mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res. 2005, 63:1-9. 10.1016\/j.eplepsyres.2004.09.005","journal-title":"Epilepsy Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/33880-acute-kidney-injury-caused-by-levetiracetam-in-a-patient-with-status-epilepticus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:41Z","timestamp":1707506801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/33880-acute-kidney-injury-caused-by-levetiracetam-in-a-patient-with-status-epilepticus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.8814","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}